Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)]

Time frame: On-treatment Week 4

Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, neutropenia as defined by ANC < 750 mm3 or thrombocytopenia as defined by platelets < 50,000 mm3)

Hb = Hemoglobin ANC = Absolute neutrophil count

Time frame: Up to week 12 or week 24

Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain)

Time frame: Up to week 12 or week 24

Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)

Time frame: Up to week 12 or week 24

Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group

Time frame: Post-treatment week 24

Proportion of subjects with on-treatment Serious adverse events (SAEs)

Time frame: Up to week 12 or week 24

Proportion of subjects with dose reductions

Time frame: Up to week 12 or week 24

Proportion of subjects who discontinue due to Adverse events (AEs)